# US 2008/0300646 A1 · Treatment of cardiomyopathy, heart failure and cardiac ischemia using stimulation induced secretion of glp-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0300646 A1
- Document ID: US20080300646A1
- Status: Published application
- Kind: A1
- Application number: 11/756,464
- Filed: 2007-05-31
- Published: 2008-12-04
- Earliest claimed: 2007-05-31
- Assignees: Pacesetter, Inc.
- Inventors: Martin Cholette
- Web page: https://patentgrep.com/patent/US20080300646A1

## CPC

- A61N 1/3627: {for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy}
- A61N 1/326: {for promoting growth of cells, e.g. bone cells}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

An exemplary method for treating heart failure includes diagnosing heart failure and calling for delivery of energy to the distal ileum to activate L cells using an implantable device where activation of L cells causes release of GLP-1 and where release of GLP-1 treats heart failure. Various other methods, devices, systems, etc., are also disclosed.

## Claims

### Claim 1

A method for increasing cardiac output, the method comprising:
detecting a need for increased cardiac output; and
calling for delivery of energy to the distal ileum to activate L cells using an implantable device wherein activation of L cells causes release of GLP-1 and wherein release of GLP-1 increases cardiac output.

### Claim 2 (depends on 1)

The method of claim 1 further comprising calling for delivery of energy to the duodenum to activate K cells using an implantable device wherein activation of K cells causes release of GIP.

### Claim 3 (depends on 2)

The method of claim 2 comprising calling for coordinated delivery of energy to the duodenum and to the distal ileum.

### Claim 4 (depends on 1)

The method of claim 1 wherein the detecting a need for increased cardiac output comprises measuring pressure.

### Claim 5 (depends on 4)

The method of claim 4 comprising calling for delivery of energy to the distal ileum to activate L cells in response to measuring a pressure that does not exceed a threshold pressure.

### Claim 6 (depends on 1)

The method of claim 1 comprising calling for delivery of energy to the distal ileum to activate L cells in response to detecting a low concentration of GLP-1.

### Claim 7 (depends on 6)

The method of claim 6 wherein the concentration of GLP-1 comprises a gastrointestinal concentration or a blood concentration.

### Claim 8 (depends on 1)

The method of claim 1 comprising calling for delivery of energy to the distal ileum to activate L cells in response to detecting a high in vivo concentration of glucose.

### Claim 9 (depends on 8)

The method of claim 8 wherein the concentration of glucose comprises a gastrointestinal concentration or a blood concentration.

### Claim 10

A method to increase cardiac output, the method comprising:
detecting a need for increased cardiac output; and
activating at least one member selected from a group consisting of vagal nerves, K cells and L cells by using an implantable device, wherein the activating induces, directly or indirectly, release of GLP-1 increases cardiac output.

### Claim 11 (depends on 10)

The method of claim 10 wherein the activating comprises electrical activation.

### Claim 12 (depends on 10)

The method of claim 10 wherein the activating comprises chemical activation.

### Claim 13

An implantable cardiac device comprising:
detection circuitry adapted to diagnose low cardiac output; and
stimulation circuitry adapted to call, in response to the detection circuitry diagnosing the low cardiac output, for delivery of energy to the distal ileum to activate L cells wherein activation of L cells causes release of GLP-1 and wherein release of GLP-1 increases cardiac output.

### Claim 14 (depends on 13)

The device of claim 13 wherein the stimulation circuitry is further adapted to call for delivery of energy to the duodenum to activate K cells wherein activation of K cells causes release of GIP.

### Claim 15 (depends on 14)

The device of claim 14 wherein the stimulation circuitry is adapted to call for coordinated delivery of energy to the duodenum and to the distal ileum.

### Claim 16 (depends on 13)

The device of claim 13 wherein the stimulation circuitry is adapted to call for delivery of energy to the distal ileum to activate L cells in response to the detection circuitry detecting a high concentration of glucose.
